Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GRN | P28799 | 1/20 | 0.31 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14037264 | 0.81 | CYP2C19 (0.36) | CYP2C9CYP2C19TSHRMTORHRH4 | |
| SCHEMBL18871348 | 0.81 | CYP2C9 (0.36) | CYP2C9CYP2C19TSHRMTORHRH4 | |
| SCHEMBL2611129 | 0.78 | TSHR (0.39) | CYP2C9CYP2C19TSHRMTORHRH4 | |
| SCHEMBL24311782 | 0.78 | CYP2C9 (0.34) | CYP2C9CYP2C19TSHRMTORHRH4 | |
| SCHEMBL13944416 | 0.78 | CYP2C9 (0.38) | CYP2C9CYP2C19TSHRMTORHRH4 | |
| SCHEMBL25015250 | 0.78 | CYP2C9 (0.38) | CYP2C9CYP2C19TSHRMTORHRH4 | |
| SCHEMBL14415969 | 0.76 | CYP2C9 (0.46) | CYP2C9CYP2C19TSHRMTORHRH4 | |
| SCHEMBL13563919 | 0.76 | TSHR (0.33) | CYP2C9CYP2C19TSHRMTORHRH4 | |
| SCHEMBL13563924 | 0.74 | CYP2C9 (0.36) | CYP2C9CYP2C19TSHRMTORHRH4 | |
| SCHEMBL1045230 | 0.74 | CYP2C9 (0.36) | CYP2C9CYP2C19TSHRMTORHRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 408 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250368586-A1 | PROCESSES FOR CONVERTING UNSATURATED POLYETHYLENE TO ALKENE PRODUCTS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2025-12-04 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240216515-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2024-07-04 | — | — | US | disclosed |
| US-12024500-B2 | Five-membered ring-substituted pyridazinol compounds and derivatives, preparation methods, herbicidal compositions and applications thereof | QINGDAO KINGAGROOT CHEMICAL COMPOUND CO., LTD. (CN) | 2024-07-02 | — | — | US | disclosed |
| WO-2024044713-A1 | NAPHTHYRIDINE COMPOUNDS FOR INHIBITION OF RAF KINASES | ENLIVEN INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| US-20230399297-A1 | Novel Glutamine Analogs | JACOBIO PHARMACEUTICALS CO., LTD (CN) | 2023-12-14 | — | — | US | disclosed |
| US-20230399297-A1 | Novel Glutamine Analogs | JACOBIO PHARMACEUTICALS CO., LTD (CN) | 2023-12-14 | — | — | US | disclosed |
| US-11820773-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-20230357208-A1 | MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS | Epizyme, Inc. (US) | 2023-11-09 | — | — | US | disclosed |
| US-7368453-B2 | Quinazolinone compounds with reduced bioaccumulation | CHIRON CORPORATION (US) | 2008-05-06 | — | — | US | disclosed |
| US-7351735-B2 | Benzofuran and benzothiophene derivatives useful in the treatment of hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-04-01 | — | — | US | disclosed |
| US-20080064718-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2008-03-13 | — | — | US | disclosed |
| US-20080004273-A1 | Inhibitors of protein tyrosine kinase activity | METHYLGENE, INC. (CA) | 2008-01-03 | — | — | US | disclosed |
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. | 2007-08-23 | — | — | US | disclosed |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. | 2007-01-04 | — | — | US | disclosed |
| US-6627758-B2 | Ligand including (i) at least two different types of heteroatoms selected from nitrogen, phosphorus, and sulfur, and (ii) at least one of imidazole, pyrazole, and pyridine; transition metal complex for carbonylation to aldehyde | SAN DIEGO STATE UNIVERSITY FOUNDATION | 2003-09-30 | — | — | US | disclosed |
| WO-2002066425-A2 | COMPOSITIONS AND METHODS FOR HYDRATION OF TERMINAL ALKYNES | SAN DIEGO STATE UNIVERSITY FOUNDATION (US) | 2002-08-29 | — | — | WO | disclosed |
| US-20020115860-A1 | Compositions and methods for hydration of terminal alkynes | SAN DIEGO STATE UNIVERSITY FOUNDATION (US) | 2002-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12024500-B2 | Five-membered ring-substituted pyridazinol compounds and derivatives, preparation methods, herbicidal compositions and applications thereof | DDT, CYP3A5, CYP4B1 | CYP2C9 16/4885CYP2C19 20/4885TSHR 1354/4885 |
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ERBB2, LCK, SRC | CYP2C9 712/4885CYP2C19 426/4885TSHR 287/4885 |
| US-20230357208-A1 | MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS | EP300, KAT2A, KAT6A | CYP2C9 4700/4885CYP2C19 4848/4885TSHR 3589/4885 |
| US-20020115860-A1 | Compositions and methods for hydration of terminal alkynes | CYCS, MYB, POLN | CYP2C9 3345/4885CYP2C19 2295/4885TSHR 4483/4885 |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | HGF, MET, FLT1 | CYP2C9 4759/4885CYP2C19 4590/4885TSHR 396/4885 |
| US-20230399297-A1 | Novel Glutamine Analogs | GLUL, GATD3, GLS | CYP2C9 4043/4885CYP2C19 4000/4885TSHR 3476/4885 |
| US-20080064718-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | HGF, ERBB2, MET | CYP2C9 4358/4885CYP2C19 4235/4885TSHR 1253/4885 |
| US-11820773-B2 | Tricyclic compounds | SLC10A1, PKD1, CEL | CYP2C9 14/4885CYP2C19 11/4885TSHR 2105/4885 |
| US-20240216515-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | PNLIP, LIPA, PHOSPHO1 | CYP2C9 3783/4885CYP2C19 4004/4885TSHR 2016/4885 |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | CYP2C9 10/4885CYP2C19 20/4885TSHR 728/4885 |
| US-20080004273-A1 | Inhibitors of protein tyrosine kinase activity | HGF, ERBB2, MET | CYP2C9 4358/4885CYP2C19 4235/4885TSHR 1253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.